From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials.
Heemskerk
Jill
J
Technology Development Program, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892, USA. jiil_heemskerk@ninds.nih.gov
Tobin
Allan J
AJ
Ravina
Bernard
B
D000818:Animals; D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000941:ethics / Q000639:trends*; D004195:Disease Models, Animal; D015195:Drug Design; D004341:Drug Evaluation / Q000941:ethics / Q000639:trends*; D004353:Drug Evaluation, Preclinical / Q000941:ethics / Q000639:trends*; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D011237:Predictive Value of Tests; D018570:Risk Assessment / Q000941:ethics / Q000592:standards